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Hydrofluoroalkane-134a (HFA-134a) is a new chlorofluorocarbon (CFC)-free propellant for use in metered dose 
inhalers. It provides a more environmentally friendly alternative to CFC propellants because it does not contain 
chlorine which is responsible for ozone depletion by CFCs. Beclomethasone dipropionate (BDP) is widely used for 
inhalation asthma therapy and is most commonly delivered by a CFC propellant system. The present study 
evaluated the acute safety of BDP formulated with the new propellant (HFA-134a BDP) compared with BDP in a 
CFC-11112 formulation by measuring the acute bronchial response in asthmatic patients. 
The study was conducted as a randomized, single-blind, placebo-controlled, four-period cross-over trial. 
Asthmatic patients received eight inhalations of four treatment regimens (HFA-134a BDP, 1600 mg total dose; 
CFC-1 l/12 BDP, 2000 mg total dose; HFA-134a placebo and CFC-I l/12 placebo) in random order over four study 
days. Forced expired volume in 1 s (FEV,) was measured before and 2, 10, 20,40 and 60 min after inhalation of the 
study treatments. The number of coughs was counted from the start of the first inhalation to 60 s after the last 
inhalation. 
There were no statistically significant differences between the treatment groups for changes in FEV,, for the 
number of coughs or for the occurrence or severity of bronchoconstriction. 
In asthmatic patients withholding bronchodilators, the new HFA-134a BDP propellant system proved as safe and 
was as well tolerated as the current CFC-I l/12 BDP system. The two propellant systems without active drug were 
also equally well tolerated. 
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Introduction 
Chlorofluorocarbons (CFCs) are used as propellants 
in metered dose inhalers (MDIs) which are the most 
frequently used delivery system for administration of drugs 
used in the treatment of asthma. The commonest CFCs in 
use are CFC 11 and 12. The important role that chlorine 
from CFCs plays in reducing the concentration of 
stratospheric ozone has been widely publicised (1). In 
response to the Montreal Protocol, which was established 
to reduce and eventually eradicate CFC production, an 
MD1 containing beclomethasone dipropionate (BDP) 
reformulated using a CFC-free propellant, hydrofluoro- 
alkane 134a (HFA-134a), has been developed. 
Beclomethasone dipropionate is a synthetic halogenated 
corticosteroid which has been available since 1972 for use 
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as an inhaled anti-inflammatory agent in the treatment of 
asthma. At present, it is most commonly delivered in a CFC 
propellant system; over 9 million are sold each year in the 
U.K. (Intercontinental Medical Statistics Limited). There 
are occasional reports in the literature of inhaled cortico- 
steroids being associated with cough, wheezing and 
bronchoconstriction (2-6). Studies comparing the 
propellants HFA and CFC, without BDP present, show a 
very low frequency of these side-effects in normal healthy 
volunteers (7,8). 
We undertook a study to evaluate the tolerability and 
acute safety of BDP formulated with the new propellant 
(HFA-134a BDP) compared with BDP in a CFC-11/12 
formulation by measuring the acute bronchial response in 
patients with asthma withholding use of bronchodilators. 
Methods 
STUDYPATIENTS 
Adult patients with moderate asthma, who had been 
inhaling 400-16OOpg budesonide daily for at least the 
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previous 6 months, took part in the study. Patients had 
stable, well-controlled asthma without exacerbations dur- 
ing the previous 3 months and each showed at least a 15% 
increase in forced expired volume in 1 s (FEVJ within 
15 min of inhalation of 200,ug of an inhaled P-agonist. 
Patients were taught satisfactory inhaler technique using a 
list of instructions from a patient information leaflet and 
were observed using their inhaler by a technician at each 
visit. Patients had to be capable of withholding their usual 
bronchodilator therapy for 6 h prior to each study day. 
Patients were excluded if they were pregnant, had signifi- 
cant systemic or pulmonary disease other than asthma, had 
a recent respiratory tract infection, used ,$-antagonists, 
ACE inhibitors, theophylline, oral &agonists, terbutaline 
(by subcutaneous infusion) or had used inhaled BDP dur- 
ing the previous 6 months. Patients who had a history of 
dependency on drugs or alcohol or who had smoked during 
the previous year were also excluded. 
The study was approved by the Research and Ethics 
Sub-Committee, Birmingham Heartlands Hospital, and 
written informed consent was obtained from each patient 
who volunteered for the study. 
SAMPLE SIZE 
For this study, treatments were considered to be equivalent 
if the mean percentage change in FEV, after inhalation of 
the ‘test’ treatment (HFA-134a formulations) was no more 
than 15% different (twice the usual SD in FEV, measure- 
ments) from the ‘reference’ treatment (CFC-1 l/12 formu- 
lations). In a previous study, the estimate of the within- 
subject SD of percentage change in FEV, after 
inhalation of BDP was 6%. Based on this we calculated that 
16 evaluable patients would provide three simultaneous 
90% confidence intervals, each with a total width of less 
than 30%. The estimate of 6% was validated by a blinded 
interim analysis after 16 patients completed the study. The 
study had 95% power for concluding equivalence between 
the treatments with the within-subject SD of 6% and an 
equivalence definition of within 15%. 
STUDY DESIGN 
The study was of randomized, single-blind, placebo- 
controlled, four-period cross-over design, comparing lung 
function and symptom responses. 
To optimize blinding (as in this study design the use of 
double dummies was precluded), dosing of study treatments 
took place in a separate room from the pulmonary function 
laboratory. Patients and the dosing supervisor were 
blinded only to which treatment was active or placebo 
because the HFA and CFC adapters were different in 
appearance. A second supervisor, blinded to all treatments, 
was responsible for the pulmonary function tests. 
METHODS 
Study days were separated by a minimum of 48 h. Study 
procedures started at the same time on each study day 
( f 2 h). Patients withheld their bronchodilator therapy 
(inhaled salbutamol, terbutaline or oxitropium) for 6 h 
prior to each study day. 
All eligible patients were randomly assigned a sequence 
of four treatment regimens, each contained in an MDI. 
Depending upon their sequence, patients received eight 
inhalations at 45 s intervals of each of the following treat- 
ments on study days 1,2, 3 and 4, each dose being delivered 
under supervision: 
1. 8 x 2OOpg HFA-I34a BDP (QVAR@, 3M Pharma- 
ceuticals, Loughborough, UK, total dose 1600 pg); 
2. 8 x 25Opg CFC-11/12 BDP (Allen and Hanburys, 
Greenford, UK; total dose 2000 pg); 
3. 8 x HFA-134a placebo; 
4. 8 x CFC-1 l/l2 placebo. 
Each active drug was given as eight inhalations of the 
highest strength inhaler available. 
On study day 1, patients were required to rest for at 
least 15 min before a pre-dose FEV, measurement was 
performed. FEV, was measured using a dry bellows 
spirometer in accordance with the American Thoracic 
Society Guidelines (9). The best of three reproducible 
(within 100 ml) values were used in the analysis. FEV, 
measurements were taken at 2, 10, 20, 40 and 60 min 
post-inhalation. Following the final FEV, measurement, 
patients resumed their normal therapeutic regimen until the 
next study day. Pre-dose FEV, measurements on study 
days 2, 3 and 4 were required to be within f 15% of the 
pre-dose FEV, measured on study day 1. 
On each study day the number of times that any patient 
coughed was counted from the beginning of the first 
inhalation to 60 s after the eighth inhalation, the cumulative 
number of coughs being used for analysis. 
Haematology, serum chemistry and urinalysis, a physical 
examination and a standard 12-lead electrocardiogram 
were performed at the pre-study day and at the end of the 
fourth study day. Adverse events were recorded throughout 
the study. 
ANALYSIS 
The primary safety parameter for this study was percentage 
change in FEV, from baseline up to 1 h after study drug 
administration on each study day. This was calculated as 
follows: 
(FEV, pre-dose - FEV, post-dose) x lOO/(FEV, pre-dose) 
A blinded analysis of FEV, data was performed when 
16 patients had completed the study. This analysis was 
performed to ensure that the assumptions for the sample 
size calculation were met. The analysis was performed 
without breaking the blind and, therefore, no adjustment 
was made to the type 1 error. 
The percentage change from pre-dose FEV, was com- 
pared between treatment groups using an analysis of vari- 
ance (ANOVA) for a four-period cross-over design with 
sequence, subject within sequence, treatment and period as 
factors in the model. 
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Three treatment comparisons, involving active and 
placebo formulations of HFA-134a, were of interest: 
1. HFA-I34a BDP vs. CFC-11/12 BDP; 
2. HFA-134a BDP vs. HFA-134a placebo; 
3. HFA-134a placebo lils. CFC-1 l/12 placebo. 
The null hypothesis was that the treatment mean percent- 
age changes in FEV, were not equivalent (within 5 15%). 
Rejection of this hypothesis implies equivalence of the 
treatment means. 
In each comparison, the first treatment listed is referred 
to as the ‘test’ treatment and the second as the ‘reference’ 
treatment. The ‘test’ mean was considered to be equivalent 
to the ‘reference’ mean if the 90% confidence interval (CI) 
for the difference between the two means was contained 
within an interval of & 15%. 
The null hypothesis of equal mean number of cough 
counts was tested using an ANOVA. Cough counts were a 
secondary safety parameter and were counted from the 
beginning of the first inhalation to 60 s after the eighth 
inhalation. Rejection of the null hypothesis implies a 
difference between treatments in mean cough counts. 
Equivalence testing was done only for the percentage 
change in FEV,; all other hypothesis tests were to test for 
differences between treatments. 
Results 
Of 18 patients enrolled into the study, a total of 16 patients 
(two men, 14 women) completed all four study days. Their 
mean ( f SD) age was 50 ( f 15) years. Two patients 
withdrew: one patient violated the protocol on entry to 
the study by taking > 1600 mg budesonide and was with- 
drawn after completing study day 1; the second patient 
withdrew consent after completing study day 1 due to work 
commitments. 
There were no statistically significant differences at 
the 5% level in the treatment sequence for any of the 
demographic characteristics evaluated (Table 1). 
FEV, VALUES 
There were no significant differences between the mean 
pre-dose FEV, values for the four treatment groups 
(P=O.825; Table 2) and no significant overall treatment 
effects with respect to the percentage change from pre-dose 
in FEV, at each of the post-dose assessments (P>O.O5; 
Fig. 1). For each of the comparisons of interest, the 90% CI 
for the difference between the ‘test’ mean and ‘reference’ 
mean was well contained within the f 15% interval. There- 
fore, the study treatments were equivalent with respect to 
the change from pre-dose FEV, for each of the three 
comparisons made (Table 2). 
On eight occasions, five patients experienced falls in 
FEVi of 2 15% which were considered clinically significant 
by the investigator. There was no difference between the 
study treatments in the incidence of these falls (PzO.682; 
Table 3). 
TABLE 1. Demographic characteristics 
Characteristic n=l6 
Gender 
Male IZ (%) 
Female n (%) 
Asthma duration 
l-5 yr II (%) 
>5 yr II (%) 
Age (years) 
Mean 
Range 
Height (cm) 
Mean 
Range 
Weight (kg) 
Mean 
Range 
2 (13%) 
14 (88%) 
2 (13%) 
14 (88%) 
50 
19-68 
166 
149-183 
68 
41-89 
COUGH COUNTS 
Cough counts experienced by patients ranged from 0 
(several patients on all study treatments) to 92 (one patient 
receiving CFC-11/12 BDP). The overall treatment effect 
was nearly significant, with a trend for the counts to be 
higher in patients receiving the CFC-11112 treat- 
ments (P=O.O61; Table 4). However, none of the pairwise 
treatment comparisons was significant. 
OTHER OUTCOMES 
Adverse events almost exclusively involved the respiratory 
system. Cough was reported by five patients, upper respir- 
atory infection by two, a tight chest by one and bouts of 
sneezing by one (Table 5). There was no pattern to the 
adverse events reported and no evidence of them being 
more common in one treatment group than another. There 
were no significant abnormalities in the serum biochemistry 
or haematology. 
Discussion 
This study evaluated the acute safety of BDP formulated 
with a new CFC-free propellant, HFA-134a, by comparing 
it with a CFC-BDP formulation and HFA-134a placebo. In 
previous studies, the two propellants, HFA-134a and CFC- 
11112, were investigated and had been shown to be equally 
safe in normal healthy volunteers (7,8). The present study 
compared the same propellants, both with and without the 
active drug, in patients with asthma, whose airways will be 
more sensitive to any irritant effects. Moreover, the patients 
recruited were regular budesonide users so had not 
previously been sensitized, or developed tolerance, to BDP. 
The study design allowed direct comparison of the effects 
of both formulations on each individual patient by using a 
cross-over design. Any carry-over effects were thought to be 
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TABLE 2. Difference in percentage change from pre-dose FEV, at five time points post-dose 
Comparison 
of interest 
(test vs. reference*) 
Mean 
baseline 
FEV, litres 
6”) 
Difference in mean % change from pre-dose FEV, 
(SE) (90% CIt} [P-valuei] 
Min post-dose 
2 10 20 40 60 
HFA-BDP vs. CFC-BDP 
HFA-BDP vs. HFA-placebo 
HFA-placebo vs. CFC-placebo 
2.20 
(ii) 
- 1.2 - 0.3 1.1 3.4 
(0.74) (2.8) (2.9) (2.1) (2.3) 
2.21 { - 3.8, 4.1) { - 58, 3.4) { - 5.1, 4.4) { - 2.4, 4.6) { - 0.34, 7.2) 
(0.80) [CO.OOl] [<O.OOl] [<O.OOl] [~O~OOl] [<O.OOl] 
2.20 
(0.74) (Z) (2) 
- 0.2 
(2.9) (E) (2) 
2.21 {0.6, 7.3) I1.3, 7.9) { - 5.0, 4.5) { - 2.3, 4.7) { - 0.54, 7.0) 
(0.82) [<O.OOl] [<O.OOl] [<O.OOl] [<O.OOl] [<O.OOl] 
2.21 - 2.9 - 3.7 - 0.8 - 0.04 
(0.82) (2.4) (2.8) (Z) (2.1) (2.4) 
2.24 { ; ;9,ll} { - 8.3, O.S} { - 2.5, 7.0) { - 4.3, 2.7) { - 4.0, 3.9) 
(0.8 1) < ’ [<O.OOl] [<O.OOl] [<O.OOl] [<O.OOl] 
*The reference mean is the mean of the second treatment listed in the comparison. 
t90% CI for difference. 
$P<O.OOl for all times and all comparisons. The P-value results from the test of the null hypothesis that the ‘test’ mean was . 
more than 15% different from the ‘reference’ mean. Rejection at the 0.05 level implies acceptance of the alternative hypothesis 
that the two treatment groups are equivalent. 
k% 
p 5 
a 41 T 
~~~~~~~~ 
8 ---- I. -5- 
d -6- I” P 
I I I I I 
' -70 2 lo 20 30 40 50 60 2 z ‘Time after inhalation of study drug (min) 
FIG. 1. Mean percentage change from pre-dose FEV, 
over time (P~0.05 at each time point). (-, HFA-134A 
BDP; - - -, HFA-134A placebo; - - - - -, CFC 11112 BDP; 
- . - . -, CFC 11112 placebo.) 
negligible because patients received a single dose separated 
by at least 48 h of normal asthma therapy. Indeed, sequence 
effects were found not to be statistically significant. Patients 
received the highest daily dose of BDP a patient would be 
expected to take, representing 2000pg CFC-1 l/12 BDP 
and 16OOFg of HFA-134a BDP. The highest strength of 
CFC-BDP for Becloforte is 25Opg, while the highest 
strength available for HFA-134a BDP was 200,~g. The 
inhalers were compared on a puff-for-puff basis, i.e. 
8 x 25Opg for CFC-BDP and 8 x 2OOpg for HFA-134a 
BDP. 
The CFC and HFA inhalers used in this study were not 
identical in design owing to the physico-chemical properties 
of the HFA propellant on several aspects of the mechanical 
system (10). The HFA preparations did not contain a 
surfactant because HFA does not dissolve conventional 
surfactants (the BDP in the HFA inhaler is a solution of 
BDP). In contrast, the CFC preparations contained oleic 
acid as a surfactant. Furthermore, the valve on the HFA 
MD1 did not contain a conventional neoprene diaphragm, 
which has been demonstrated to be adversely affected by 
the HFA propellant; the seal material was manufactured 
from a new elastomer which was compatible with HFA 
propellant. 
We demonstrated no statistically significant differences 
between the propellants for changes in FEV, or the number 
of coughs. The CFC-free system was as safe and as well 
tolerated as the CFC system containing BDP or placebo in 
patients who required anti-inflammatory therapy and who 
were withholding bronchodilator medication. 
The number of coughs was counted over a short period 
(from the beginning of the first inhalation to 1 min after the 
last inhalation) to try to distinguish between coughs directly 
related to inhalation of the treatments and those caused by 
other factors. On the whole, cough counts were low and, 
although there was a trend for them to be higher in the 
CFC-1 l/12 treatment periods, there was no statistically 
significant difference between the groups. 
Paradoxical bronchoconstriction has been reported with 
various MD1 products. A recent study (11) of 11,850 
patients with asthma, to assess the frequency of paradoxical 
bronchoconstriction to CFC MDIs containing the 
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TABLE 3. Subjects with falls in FEV, of 2 15% 
Subject 
identification 
number 
HFA-BDP 
(n= 16) 
Fall from pre-dose FEV, (time post-dose) 
CFC-BDP HFA-placebo CFC-placebo 
(n= 16) (n= 16) (n= 16) 
107 29.9% 20.6% 21.0% 
(2 mm) (2 min) (20 min) 
111 17.3% 
(10 min) 
112 17.2% 
(60 min) 
115 16.7% 
(10 min) 
116 150% 21.3% 
(2 min) (20 min) 
TABLE 4. Cough counts for four study treatments 
Cough counts 
HFA-BDP CFC-BDP HFA-placebo CFC-placebo 
(n=16) (n=16) (n= 16) (n= 16) P-value* 
Mean 5 8 4 8 0.061 
Median 0 2 0 5 
SE 0.63 0.71 0.47 0.68 
Min-max o-74 O-92 o-33 O-72 
Subjects with 2 1 cough (n) 7 10 7 9 
*The P-value is based on the overall test of treatment from ANOVA for a four-period cross-over. 
TABLE 5. Adverse events affecting the respiratory system 
Adverse event 
Number of subjects (subject identification numbers) 
HFA-BDP CFC-BDP HFA-placebo CFC-placebo 
Cough 4 (101, 102, 109, 116) 2 (109. 113) 2 (109, 113) 3 (102, 113, 116) 
Tight chest 1 (205) 1 (205) 1 (205) 0 
Sneezing 1 (109) 1 (109) 1 (109) 0 
Upper respiratory tract infection 2 (106, 114) 0 0 l(114) 
surfactants oleic acid or lecithin and salmeterol xinafoate 
with lecithin, showed an overall incidence of 1.5%. 
Bronchoconstriction occurred within 5 min in these 
patients, and similar findings have been reported with BDP, 
where falls in FEV, of between 22 and 61% (2-5) have been 
shown. Shim and Williams previously suggested that the 
surfactant in BDP MDIs may be the source of coughing 
and wheezing (12). However, unlike CFC-based MDIs, 
HFA-BDP contains no added surfactant and is a solution, 
rather than a suspension, of BDP. 
In the present study there were three decreases in FEV, 
observed at 2 min post-dose, which could have been a 
reaction to the study medication, propellants or excipients. 
There were five falls in FEV, occurring for the first time at 
a later time point after inhalation. These may have been 
caused either by patients withholding their bronchodilator 
therapy for the previous 6 h or, as has been previously 
reported, the repeated deep breath and forced expiration 
required for consecutive measurements of FEV, (13). All 
decreases in FEV, were not greater or more prevalent in 
any one of the treatment groups. 
In asthmatic patients withholding bronchodilators, the 
new HFA-134a BDP propellant system proved as safe and 
was as well tolerated as the current CFC-I l/12 BDP system. 
The two propellant systems without active drug were also 
equally well tolerated. 
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